Journal: Leukemia
Article Title: Haploinsufficiency of miR-143 and miR-145 reveal targetable dependencies in resistant del(5q) myelodysplastic neoplasm
doi: 10.1038/s41375-025-02537-2
Figure Lengend Snippet: GSEA enrichment plots based on miR-143 or miR-145 expression for the BIOCARTA_GLEEVEC ( A ), BIOCARTA_MAPK ( B ), and BIOCARTA_MTOR ( C ) pathways in MDS patient CD34 + bone marrow cells. D Imatinib dose-response curves for LEN-resistant and WT MDS-L cells following treatment for 48 h, as measured by AlamarBlue assay. E Proportion of apoptotic cells as measured by Annexin V staining for LEN-resistant and WT MDS-L cells following 144 h treatment with imatinib, LEN or vehicle (DMSO). F Colony output of LEN-resistant and WT MDS-L cells in the presence of imatinib (10 μM), LEN (1 μM) or vehicle (DMSO). Effect of inhibitors of pathways downstream of IGF-1R including everolimus (mTOR inhibitor, 0.1 μM), temsirolimus (mTOR inhibitor, 0.5 μM) and trametinib (MEK1/2 inhibitor, 0.03 μM) or LEN (1 μM) or vehicle (DMSO), on del(5q) cell lines: KG1a cells ( G ) and MDS-L ( H ). I Trametinib dose-response curves for LEN-resistant and WT MDS-L cells following treatment for 48 h, as measured by AlamarBlue assay. J Proportion of apoptotic cells as measured by Annexin V staining for LEN-resistant and WT MDS-L cells following 144 h treatment with trametinib (0.03 μM), LEN (1 μM) or vehicle (DMSO).
Article Snippet: The leukemic cell lines KG1a, KG1, UT7, K562, U937, and THP1 were purchased from the American Type Culture Collection.
Techniques: Expressing, Alamar Blue Assay, Staining